NIMD

Company Overview

Snapshot

Founded in January 2015 by Anan Copty, PhD, NIMD operated with 1–10 employees. The company raised $700,000 across one funding round. In May 2015, NIMD secured its seed funding to advance its medical device technology.

Business overview

NIMD (Noninvasive Medical Devices) is a medical device startup developing localized microwave thermal ablation devices for cancer treatment. Its core technology utilizes a noninvasive localized microwave heating applicator coupled with nanoparticles placed inside tumors, designed to deliver precise energy for cancer treatment and potentially early detection. The company's first product, Hyperthermed, is a compact medical device intended for hospitals and cancer clinics to treat specific cancer types using localized hyperthermia, selectively targeting cancer cells while monitoring tumor temperature. While initially focusing on breast cancer, NIMD's technology is also applicable to skin melanomas, glioblastomas, and various head, neck, and lung cancers, operating within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is NIMD's primary focus in medical technology?

NIMD develops noninvasive localized microwave thermal ablation devices for treating cancer, utilizing a heating applicator coupled with nanoparticles to target tumors with high accuracy.

When was NIMD founded and by whom?

NIMD was founded in January 2015 by Anan Copty, PhD.

What is Hyperthermed?

Hyperthermed is NIMD's first compact, versatile medical device designed for use in hospitals and cancer clinics to treat specific types of cancer using localized hyperthermia, selectively targeting cancer cells.

Which types of cancer is NIMD's technology designed to address?

NIMD is currently focusing on breast cancer treatment, with potential applicability for skin melanomas, glioblastomas, and cancers of the chest, tongue, head, neck, and lung.

What was the company's operational status as of November 2018?

NIMD ceased to operate in November 2018.